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http://dx.doi.org/10.1016/j.kjms.201Abstract Different types of proton pump inhibitor (PPI)-based triple therapies could result
in different Helicobacter pylori eradication rates. This study aimed to compare the efficacy
and safety of rabeprazole- and lansoprazole-based triple therapies in primary treatment of
H. pylori infection. From September 2005 to July 2008, 426 H. pylori-infected patients were
randomly assigned to receive a 7-day eradication therapy with either rabeprazole 20 mg bid
(RAC group, nZ 222) or lansoprazole 30 mg bid (LAC group, nZ 228) in combination with
amoxicillin 1 g bid and clarithromycin 500 mg bid. The patients received follow-up esophago-
gastroduodenoscopy (EGD) and/or 13C-urea breath test 12e16 weeks later to define H. pylori
status. Their personal and medical history, compliance and side effects were obtained by
using a standardized questionnaire. Intention-to-treat analysis revealed that the eradication
rate was 87.84% in the RAC group and 85.96% in the LAC group (pZ 0.56). All patientst of Internal Medicine, Chi Mei Medical Center, 201, Taikang Village, Liouying Township, Tainan,
hinet.net, gi@kmu.edu.tw (J.-J. Chen).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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380 M.-K. Liu et al.returned for assessment of compliance (100% in the LAC group vs. 99.50% in the RAC group;
pZ 0.32) and adverse events (7.20% in the RAC group vs. 5.70% in the LAC group,
pZ 0.51). Univariate analysis suggested that patients with nonsteroid anti-inflammatory
agent (NSAID) use had lower eradication rates than those without (76.71% vs. 88.74%;
pZ 0.006). Our results showed that efficacy and safety were similar in rabeprazole- and
lansoprazole-based primary therapies. The influence of NSAID usage on H. pylori eradication
needs to be further investigated.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Helicobacter pylori infection causes gastrointestinal tract
diseases such as peptic ulcers, gastritis, mucosa-associated
lymphoid tissue lymphoma, and gastric cancer [1]. H. pylori
eradication was proven to cure or improve these diseases.
The eradication rate was much improved after proton
pump inhibitors (PPIs) were included in the regimens.
The Maastricht consensus report recommended PPIe
amoxicillineclarithromycin or metronidazole as the first-
line treatment for H. pylori [2]. In Taiwan, the most
widely used regimen is a PPI plus amoxicillin and clari-
thromycin; the eradication rate reaches 75e95% [3e8].
Factors that influence eradication efficacy include bacteria
strain, antibiotic resistance, and patients’ compliance [9].
PPIs are rapidly absorbed, highly protein bound, and
metabolized in the liver by the cytochrome (CYP) P450
system, especially CYP2C19 [10e12]. PPIs play an impor-
tant role in H. pylori eradication. They can affect the
treatment efficacy through two possible mechanisms.
Firstly, PPIs have antibacterial activity. Secondly, they
suppress gastric acid secretion, through which the avail-
ability and activity of antibiotics is increased [9]. A
previous study has suggested that increasing the PPI dose
could improve the eradication rate [13]. However,
different types of PPIs may have variable effects on gastric
acid suppression and antibacterial activity. Their side
effects, such as allergic reaction, dizziness, and gastroin-
testinal upset, may also influence patient compliance.
Rabeprazole has the highest pKa and fastest onset of action
[14,15]. It is metabolized through a nonenzymatic pathway
and is less susceptible to the influence of genetic poly-
morphisms of CYP2C19. Therefore, patients on rabeprazole
have similar pharmacokinetics and less drug interactions
even if they have different hepatic metabolism rates [14].
Lansoprazole was marketed earlier than rabeprazole and
has been proven to have good eradication rates and little
side effects in clinical studies [9,16]. It is metabolized
by CYP3A4 and CYP2C19. Clarithromycin significantly
increases Cmax of lansoprazole and, respectively, enhances
the drug effect by inhibition of CYP3A4 [10,11,17]. Two
Japanese studies have compared the efficacy and safety of
rabeprazole- versus lansoprazole-based regimens in
primary treatment of H. pylori infection [18,19]. However,
results were not consistent. Moreover, the H. pylori resis-
tance rates could be different in Taiwan compared with
Japan, but no report regarding this has been seen in
Taiwan.Materials and methods
Patient selection
Potential cases were patients who visited the gastroenter-
ological clinic of Kaohsiung Medical University Hospital
between September 2005 and June 2008 with a complaint
of epigastric discomfort. Esophagogastroduodenoscopy
(EGD) was performed and those diagnosed of nonulcer
dyspepsia (gastritis) or peptic ulcer with H. pylori infection
were enrolled in this study. Peptic ulcer includes both
duodenal and/or gastric ulcers. Exclusion criteria included:
(1) ingestion of antibiotics, bismuth, or PPI within the prior
4 weeks; (2) patients with allergic history to the medica-
tions used; (3) patients with previous gastric surgery; (4)
the coexistence of serious concomitant illness (e.g.,
decompensated liver cirrhosis, uremia); and (5) female
patients who were pregnant.
Treatment regimen, randomization, and follow-up
The participants were randomly assigned to the RAC group
(rabeprazole 20 mg bid, amoxicillin 1 g bid, and clari-
thromycin 500 mg bid for 7 days) or the LAC group (lanso-
prazole 30 mg bid, amoxicillin 1 g bid, and clarithromycin
500 mg bid for 7 days) according to the random number
table. By starting from a certain row and column of the
random number table, the serially enrolled patients ob-
tained a number. Those with odd numbers were assigned to
the RAC group and the opposite were assigned to the LAC
group. Patients were asked to return during the 2nd week to
assess drug compliance and adverse effects. The technicians
whoperformed theH.pylori tests [culture, rapidurease test,
and 13C-urea breath test (UBT)] or filled in the questionnaires
as well as the pathologists were blinded to the eradication
regimens the patients received. All participants gavewritten
informed consent. This study was approved by the Institu-
tional Review Board of Kaohsiung Medical University.
Diagnosis of H. pylori infection
All participants underwent a UBT and EGD examination with
biopsy of the gastric mucosa to establish H. pylori infection
by rapid urease test, histology examination of H. pylori by
haematoxylin and eosin stains and Giemsa stains, and
H. pylori culture. The definition of H. pylori infection in
this study required positive H. pylori culture or at least two
PPI and H. pylori treatment 381positives of UBT, rapid urease test, and histology exami-
nation. Patients were asked to receive EGD examinations
with biopsy for rapid urease test, histology, and culture
12e16 weeks later to confirm H. pylori infection status.
Failed H. pylori eradication was established if the culture
was positive, or both rapid urease test and histology were
positive. For patients who refused follow-up EGD, UBT was
used to confirm H. pylori status.
Questionnaire
The questionnaire contained questions regarding personal
history of smoking, alcohol drinking, regular usage of
nonsteroid anti-inflammatory drug (NSAID), and presence of
underlying systemic diseases. Smokers were those who
consumed more than one pack of cigarettes a week and
drinkers were those who drank more than one cup of
alcoholic beverage a day. Regular NSAID users were defined
as continuous consumption of NSAIDs for pain control for
more than 1 month. In this study, they were also current
users. Underlying systemic diseases included hypertension,
diabetes mellitus, cerebral vascular accident, heart
disease, chronic obstruction pulmonary disease, uremia,
malignancy, viral hepatitis, and others. Compliance was
defined as good (taken more than 70% of total medication)
or poor by counting unused medication after treatment was
completed. Adverse events included abdominal pain, diar-
rhea, constipation, dizziness, taste perversion, headache,
anorexia, nausea, vomiting, skin rash, and others. Those
who considered that those symptoms disturbed their daily
life were defined to have positive adverse effects. Those
who did not experience these symptoms or did experience
them but did not consider them a disturbance to their daily
life were defined as negative adverse effects.
Statistical analysis
The distribution of gender and the initial endoscopic diag-
nosis between patients in RAC and LAC groups were
compared by Chi-square statistics. The same method was
applied to compare the efficacy and the frequency of side
effects of the two regimens. The analyzed efficacy outcome
was cure of H. pylori infection. The difference of patients’
ages in the two groupswas examined using the Student t test.
Subanalysis for aging, smoking, alcohol consumption, and
NSAID use related to efficacy of H. pylori eradication
was performed by Chi-square analysis. A two-sided
p value< 0.05 was considered statistically significant. The
data were analyzed using the SAS statistical package version
9.1 (SAS Institute, Cary, NC); all p values were two-sided.
Assuming that the conventional eradication rate (LAC
group) was 81%, and the RAC group achieved a 91% eradica-
tion rate (10% difference of increase) [19], our statistical
power in this study would have 91% under the sample size of
approximately 210 patients in each group and two-sided
p value of 0.05 if 95% of patients completed the follow-up.
Results
In total, 24 of the 474 patients enrolled were excluded
according to the exclusion criteria. A total of 426 of thoseinterviewed using a standardized questionnaire received
further H. pylori treatment. The 24 patients who refused to
receive any follow-up examination for H. pylori infection
were defined as treatment failure in intention-to-treat
analysis (Fig. 1). In Table 1, we show the demographic
characteristics of our study participants including the
distribution of age, gender, personal history, underlying
disease, and initial endoscopic diagnoses in RAC and LAC
groups. Most were diagnosed with ulcer diseases (65.32% in
the RAC group, 60.96% in the LAC group; pZ 0.34). The
prevalence of cigarette, alcohol, and NSAID consumption
was similar in each group. The efficacy and safety profiles
of the two regimens are shown in Table 2. In intention-to-
treat analysis, 87.84% (195/222) and 85.96% (196/228) of
patients in RAC and LAC groups, respectively, were free of
H. pylori infection after eradication therapy (pZ 0.56). In
per protocol analysis, the H. pylori eradication rate was
91.98% in the RAC group and 91.59% in the LAC group
(pZ 0.88). There was no difference in eradication rate in
the two groups. All study patients, except one in the RAC
group, took at least 70% of prescribed medication;
compliance was 99.5% in the RAC group and 100% in the LAC
group. Among the 16 (7.2%) cases in the RAC group who
reported adverse events, taste perversion (10 cases) and
dizziness (5 cases) were the most common. A total of 13
(5.70%) patients in the LAC group reported adverse events
and the most common complaints were taste perversion
(6 cases) and dizziness (6 cases). There were no statistically
significant differences in eradication rates, compliance
rates, or the presence of adverse events.
Smoking and alcohol consumption did not significantly
influence H. pylori eradication rates (Table 3). However,
NSAID users were less likely to have successful H. pylori
eradication than nonusers (76.71% vs. 88.74%; pZ 0.006).Discussion
Many studies have compared the effect of different PPI-
based regimens on H. pylori eradication in many countries.
A meta-analysis study in 2003 showed similar efficacy for
H. pylori eradication when different PPIs were used [20]. A
review article in China also revealed no difference in
H. pylori eradication rate using different PPIs and the
eradication rates reached around 80e90% in different
studies [21]. Two studies compared the newer PPIs, rabe-
prazole versus lansoprazole. Miwa et al. reported similar
eradication rates for RAC and LAC regimens (88.7% and
82.7%, respectively, 104 patients in both groups) [18].
However, Murakami et al. showed a significantly higher
success rate with the RAC regimen (88%, 147 patients) than
with the LAC regimen (78%, 148 patients) in intention-to-
treat analysis [19]. Our previous study revealed that the
H. pylori eradication rate reached 85e90% in intention-to-
treat analysis and there was no significant difference in
esomeprazole- and rabeprazole-based triple therapy [3].
This study also showed similar efficacy in lansoprazole- and
rabeprazole-based triple therapy (85.96% and 87.84%;
pZ 0.56).
The common side effects of PPI-based therapy include
abdominal discomforts (e.g., abdominal pain, diarrhea,
constipation, and nausea), skin rash, taste perversion,
Figure 1. Consort diagram of the study design.
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adverse effects was around 6% in both groups. Taste
perversion and dizziness were the most common among
them. One study in Japan showed a higher frequency ofTable 1 Demographic distribution of the participants
receiving different eradication regimens.
RAC group
(nZ 222)
LAC group
(nZ 228)
p
Age (y) 0.79
54 118 (53.15%) 124 (54.39%)
>54 104 (46.85%) 104 (45.61%)
Gender
Male 94 (42.34%) 83 (36.4%) 0.19
Female 128 (57.66%) 145 (63.6%)
Smokinga 32 (14.75%) 33 (14.47%) 0.94
Alcohol consumptiona 13 (5.99%) 19 (8.33%) 0.33
NSAID useb 37 (16.89%) 36 (15.86%) 0.77
Diagnosis
Gastritis 77 (34.68%) 89 (39.04%) 0.34
Peptic ulcerc 145 (65.32%) 139 (60.96%)
LACZ lansoprazole, amoxicillin, and clarithromycin; RACZ ra-
beprazole, amoxicillin, and clarithromycin.
a Missing in five cases.
b Missing in four cases.
c Peptic ulcerZ presence of gastric ulcer and/or duodenal
ulcer.adverse effects in patients receiving a higher dose of
rabeprazole-based triple therapy (4.8% in 40 mg group vs.
0% in 20 mg group). However, compliance was similar in
both groups [18]. The patients could tolerate both regimens
well and showed good compliance.
Some personal habits, such as smoking and alcohol
drinking, and some medications may cause drug interaction
via hepatic metabolism, especially via the CYP 450 system.
Previous studies including ours showed that smoking had little
effect on eradication rates. However, Hsu et al. reported that
alcohol consumption significantly lowered treatment efficacy
(70% among drinkers vs. 90% among nondrinkers, pZ 0.004)
[6]. The possible mechanism stems from the stimulation ofTable 2 Outcomes of rabeprazole- and lansoprazole-
based triple therapies.
RAC group
(nZ 222)
LAC group
(nZ 228)
p
Eradication rate
Intention-
to-treat
87.84% (195/222) 85.96% (196/228) 0.56
Per protocol 91.98% (195/212) 91.59% (196/214) 0.88
Compliance 99.50% (221/222) 100% (228/228) 0.32
Adverse events 7.20% (16/222) 5.70% (13/202) 0.51
LACZ lansoprazole, amoxicillin, and clarithromycin; RACZ ra-
beprazole, amoxicillin, and clarithromycin.
Table 3 Univariate analysis of clinical factors influencing
the efficacy of H. pylori eradication.
Patients
(n)
H. pylori
eradication rate
p
Smokinga 0.58
(þ) 65 84.61%
() 380 87.10%
Alcohol consumptiona 0.34
(þ) 32 84.38%
() 413 86.92%
NSAID useb 0.006
(þ) 73 76.71%
() 373 88.74%
a Missing five cases.
b Missing four cases.
PPI and H. pylori treatment 383histaminerelease,gastric acid secretion [22,23], andachange
of intragastric microenvironment that influences the stability
of antibiotics or enhances the growth of H. pylori [24].
However, such differences were not seen in our study (pres-
ence vs. absence of alcohol consumption: 84.38% vs. 86.92%,
pZ 0.34). A larger study with more detailed records of the
amount and type of alcohol consumed is needed to clarify the
association.
Aspirin and NSAIDs, commonly prescribed for antiathero-
sclerosis and pain control, often cause dyspepsia and have
been reported to affectH. pylori treatment. Previous studies
hypothesized that aspirin and NSAIDs could inhibit H. pylori
growth in vitro and increase its susceptibility to antibiotics
[25, 26]. A small Korean study compared the efficacy of the
standard omeprazoleeamoxicillineclarithromycin (OAC)
regimen (61 cases) with the OAC plus aspirin regimen (60
cases) and did not find a significant difference in eradication
rates (per protocol analysis: 80.3% vs. 86.7%, pZ 0.472) [25].
Recently, Zhang et al. [26] conducted a prospective
caseecontrol study in Turkey and reported a significantly
higher eradication rate of triple therapy among aspirin users
(Intention-to-treat analysis (ITT): 83% vs. 53%, p< 0.05).
However, another retrospective observational study in Korea
revealed a lower eradication efficacy for first-line treatment
among aspirin users compared with nonusers (61.4% vs.
78.7%, pZ 0.001) [27]. In that study, the eradication rate
was similar amongNSAID users andnonusers (70.8% vs. 77.2%,
pZ 0.466) [27]. Our crude result suggests that NSAID users
have lower successful eradication than nonusers (76.71% vs.
88.74%, pZ 0.006). The possible mechanism is that NSAIDs
cause gastrointestinal damage and influence blood supply of
gastric mucosa, whichmay decrease drug absorption and the
bactericidal effect. The possible confounders were smoking,
alcohol drinking,H. pylori strain (antibiotic resistance), drug
interaction, andhost susceptibility. However,wedonot have
information concerning the last three items. The distribution
of smoking and alcohol, age and gender were similar in the
two groups, and thus do not need to be further adjusted. All
inconsistent findings may come from different study pop-
ulations, bacteria strains, limited sample size, and study
design. A larger randomized control study focusing on the
effect of NSAIDs or aspirin on the treatment for H. pylori is
needed to clarify the association.The strengths of this study include: (1) this was a well-
designed randomized trial with adequate study cases and
considered some factors that may influence the results of
H. pylori treatment; (2) the H. pylori status was confirmed
by methods proven to have high accuracy to detect current
infection; and (3) the compliance and adverse effects were
carefully recorded soon after the patients finished the
treatment course to avoid recall bias. However, we did not
perform the H. pylori sensitivity test. Neither did we test
the genetic polymorphisms concerning CYP 2C19, which
might influence the metabolism of PPIs.
In conclusion, this study showed similar eradication
rates for rabeprazole- and lansoprazole-based primary
therapies for H. pylori infection. Both regimens were well
tolerated and had good patient compliance. NSAIDs might
decrease the efficacy of first-line therapy but this finding
should be confirmed by a larger prospective study.Acknowledgments
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